Affiliation:
1. Department of Psychiatry, Washington University School of Medicine, St.
Louis, MO, USA
2. Department of Neurology, Washington University School of Medicine, St.
Louis, MO, USA
Abstract
AbstractSerotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of
indications including depressive disorders, anxiety, and chronic pain. Besides
inhibiting the serotonin transporter, these medications have broad-spectrum
properties in many systems. Their roles have been studied in cancer,
Alzheimer’s disease, and infectious processes. The COVID-19 pandemic
highlighted the importance of drug repurposing of medications already in use. We
conducted a narrative review of current evidence and ongoing research on drug
repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and
neuroprotective activity. SRIs may have clinical use as repurposed agents for a
wide variety of conditions including but not limited to COVID-19,
Alzheimer’s disease, and neoplastic processes. Further research,
particularly randomized controlled trials, will be necessary to confirm the
utility of SRIs for new indications.
Funder
PCORI and COVID Early Treatment
Fund Emergent Ventures FastGrants
EJL is a consultant for Prodeo
EJL and AMR are inventors on a patent application related to COVID-
19 research including sigma-1 receptor agonists
CFZ is on the scientific advisory board and receives stock options
from Sage Therapeutics
National Institutes of Health grant
Subject
Pharmacology (medical),Psychiatry and Mental health,General Medicine
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献